Arbor Capital Management Inc. ADV Buys Shares of 26,518 Abbott Laboratories $ABT

Arbor Capital Management Inc. ADV bought a new position in shares of Abbott Laboratories (NYSE:ABT) during the first quarter, HoldingsChannel.com reports. The firm bought 26,518 shares of the healthcare product maker’s stock, valued at approximately $2,691,000. Abbott Laboratories makes up about 2.2% of Arbor Capital Management Inc. ADV’s portfolio, making the stock its 8th biggest position.

A number of other institutional investors and hedge funds also recently modified their holdings of ABT. DMC Group LLC raised its holdings in Abbott Laboratories by 4.7% in the first quarter. DMC Group LLC now owns 3,033 shares of the healthcare product maker’s stock worth $311,000 after purchasing an additional 136 shares during the period. GreatBanc Trust CO increased its position in shares of Abbott Laboratories by 3.4% in the 1st quarter. GreatBanc Trust CO now owns 3,790 shares of the healthcare product maker’s stock valued at $389,000 after buying an additional 125 shares in the last quarter. Meadow Creek Wealth Advisors LLC increased its position in shares of Abbott Laboratories by 12.8% in the 1st quarter. Meadow Creek Wealth Advisors LLC now owns 4,141 shares of the healthcare product maker’s stock valued at $425,000 after buying an additional 471 shares in the last quarter. Peterson Wealth Services raised its stake in Abbott Laboratories by 22.8% during the 1st quarter. Peterson Wealth Services now owns 2,023 shares of the healthcare product maker’s stock worth $208,000 after buying an additional 376 shares during the period. Finally, Griffin Asset Management Inc. lifted its holdings in Abbott Laboratories by 10.1% during the first quarter. Griffin Asset Management Inc. now owns 65,442 shares of the healthcare product maker’s stock worth $6,719,000 after acquiring an additional 6,023 shares in the last quarter. 75.18% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on ABT. TD Cowen lowered their price target on Abbott Laboratories from $137.00 to $115.00 and set a “buy” rating for the company in a report on Friday, April 17th. Jefferies Financial Group decreased their price objective on Abbott Laboratories from $145.00 to $135.00 and set a “buy” rating for the company in a research report on Friday, April 17th. Daiwa Securities Group cut Abbott Laboratories from an “outperform” rating to a “neutral” rating and set a $92.00 target price for the company. in a research note on Wednesday, April 22nd. Sanford C. Bernstein dropped their target price on shares of Abbott Laboratories from $125.00 to $110.00 and set an “outperform” rating on the stock in a report on Friday, April 17th. Finally, Benchmark reduced their price target on shares of Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating for the company in a report on Friday, April 17th. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have given a Hold rating to the company. According to MarketBeat, Abbott Laboratories has a consensus rating of “Moderate Buy” and an average target price of $118.42.

Insider Activity at Abbott Laboratories

In related news, Director Daniel J. Starks acquired 10,000 shares of the company’s stock in a transaction dated Monday, April 27th. The shares were bought at an average price of $92.65 per share, for a total transaction of $926,500.00. Following the purchase, the director directly owned 6,751,103 shares in the company, valued at approximately $625,489,692.95. This trade represents a 0.15% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Philip P. Boudreau acquired 2,200 shares of the business’s stock in a transaction dated Thursday, April 23rd. The stock was bought at an average cost of $91.50 per share, with a total value of $201,300.00. Following the acquisition, the chief financial officer owned 2,200 shares in the company, valued at $201,300. The trade was a ∞ increase in their position. The disclosure for this purchase is available in the SEC filing. 0.46% of the stock is owned by insiders.

Abbott Laboratories Trading Down 0.5%

Shares of NYSE:ABT opened at $93.97 on Friday. The company’s 50-day moving average price is $89.21 and its two-hundred day moving average price is $103.24. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.39 and a quick ratio of 1.01. Abbott Laboratories has a one year low of $81.97 and a one year high of $137.49. The stock has a market capitalization of $163.69 billion, a PE ratio of 26.32, a price-to-earnings-growth ratio of 1.63 and a beta of 0.61.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share for the quarter, beating the consensus estimate of $1.14 by $0.01. The company had revenue of $11.16 billion during the quarter, compared to analysts’ expectations of $10.99 billion. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.Abbott Laboratories’s revenue for the quarter was up 7.8% compared to the same quarter last year. During the same quarter last year, the company earned $1.09 EPS. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. On average, equities analysts forecast that Abbott Laboratories will post 5.48 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th will be paid a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date is Wednesday, July 15th. Abbott Laboratories’s dividend payout ratio (DPR) is currently 70.59%.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.